BRAF and Miyoshi myopathy: The combined BRAF and MEK blockade has been evaluated in MM cases, and in the first case report on the combination of vemurafenib and cobimetinib, a patient, with highly resistant MM and harboring the BRAF V600E mutation, achieved rapid and complete response [148].